17.10
前日終値:
$17.79
開ける:
$17.82
24時間の取引高:
9.86M
Relative Volume:
2.60
時価総額:
$1.81B
収益:
$2.18B
当期純損益:
$-64.32M
株価収益率:
-17.74
EPS:
-0.9641
ネットキャッシュフロー:
$91.18M
1週間 パフォーマンス:
-4.20%
1か月 パフォーマンス:
-13.46%
6か月 パフォーマンス:
-19.23%
1年 パフォーマンス:
-26.74%
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
名前
Sarepta Therapeutics Inc
セクター
電話
617-274-4000
住所
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc
|
17.10 | 1.81B | 2.18B | -64.32M | 91.18M | -0.9641 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
|
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-07-09 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2026-01-28 | 再開されました | Barclays | Equal Weight |
| 2025-12-09 | 開始されました | Wedbush | Outperform |
| 2025-11-05 | アップグレード | Mizuho | Neutral → Outperform |
| 2025-09-22 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | アップグレード | Barclays | Underweight → Equal Weight |
| 2025-07-29 | 開始されました | Bernstein | Mkt Perform |
| 2025-07-29 | 繰り返されました | H.C. Wainwright | Sell |
| 2025-07-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2025-07-29 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-07-28 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2025-07-25 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2025-07-24 | 開始されました | Citigroup | Sell |
| 2025-07-23 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2025-07-22 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-07-21 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2025-07-21 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | ダウングレード | Mizuho | Outperform → Neutral |
| 2025-07-21 | ダウングレード | Needham | Hold → Underperform |
| 2025-07-21 | ダウングレード | UBS | Buy → Neutral |
| 2025-07-18 | ダウングレード | Needham | Buy → Hold |
| 2025-06-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-06-17 | 開始されました | Wolfe Research | Peer Perform |
| 2025-06-16 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-06-16 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | ダウングレード | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2025-04-11 | 開始されました | Wells Fargo | Overweight |
| 2025-04-02 | アップグレード | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 開始されました | Deutsche Bank | Hold |
| 2024-11-27 | 繰り返されました | Needham | Buy |
| 2024-11-25 | 開始されました | H.C. Wainwright | Sell |
| 2024-11-07 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | 開始されました | Jefferies | Buy |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-07-29 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-05-31 | 開始されました | Piper Sandler | Overweight |
| 2024-05-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-01-31 | 開始されました | BMO Capital Markets | Outperform |
| 2023-12-13 | 再開されました | Citigroup | Buy |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-11-21 | 開始されました | Wedbush | Outperform |
| 2023-10-31 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-06-23 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2023-04-26 | 開始されました | SMBC Nikko | Outperform |
| 2023-04-04 | 開始されました | Citigroup | Buy |
| 2023-03-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | 繰り返されました | BTIG Research | Buy |
| 2022-12-16 | アップグレード | UBS | Neutral → Buy |
| 2022-04-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-01-05 | 繰り返されました | Needham | Buy |
| 2021-12-09 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-11-05 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-09-15 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-08-05 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Neutral |
| 2021-01-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-01-11 | ダウングレード | UBS | Buy → Neutral |
| 2021-01-08 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2021-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 開始されました | Berenberg | Hold |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-08-20 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | 開始されました | Mizuho | Buy |
| 2019-11-01 | 開始されました | Guggenheim | Buy |
| 2019-08-21 | 繰り返されました | Needham | Buy |
| 2019-07-09 | 繰り返されました | Morgan Stanley | Overweight |
| 2019-07-01 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-11 | 繰り返されました | Credit Suisse | Outperform |
| 2018-10-12 | 開始されました | Bernstein | Outperform |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-26 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2018-09-14 | 再開されました | BofA/Merrill | Buy |
| 2018-09-06 | 開始されました | Credit Suisse | Outperform |
| 2018-08-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | 繰り返されました | Robert W. Baird | Outperform |
| 2018-06-20 | 繰り返されました | Needham | Buy |
| 2018-06-19 | 繰り返されました | H.C. Wainwright | Buy |
すべてを表示
Sarepta Therapeutics Inc (SRPT) 最新ニュース
Top Research Reports for SpaceX, Dell & KLA Corp. - Zacks Investment Research
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
A treatment was linked to better movement over 2 years in boys ages 8 to 12 with Duchenne - Stock Titan
LB Pharmaceuticals Inc (LBRX) Stock Price & News - Syfe
Neurogene Inc. (NGNE) Stock Price & News - Syfe
Sarepta Therapeutics, Inc.Common Stock (NQ: SRPT - The Chronicle-Journal
Sarepta Therapeutics Drops 5.5% Amid Sector-Wide Selling - AlphaStreet
Sarepta Therapeutics Drops 5.5% Amid Sector-Wide Selling - AlphaStreet
SRPT Looks 79.1% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Sarepta Therapeutics climbs 10%, rebounding from recent slide (SRPT:NASDAQ) - Seeking Alpha
Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving High - Benzinga
IRWD Stock Price, Quote & News - Syfe
H.C. Wainwright reiterates Sarepta stock Sell rating at $5 target By Investing.com - Investing.com Canada
AQST Stock Price, Quote & News - Syfe
Sarepta (NASDAQ: SRPT) CFO now holds 121,792 shares after tax withholding - Stock Titan
Tax on stock award trims Sarepta (NASDAQ: SRPT) EVP stake to 115,519 shares - Stock Titan
Sarepta (SRPT) COO reports tax share withholding after RSU vesting - Stock Titan
Jefferies reiterates Sarepta Therapeutics stock rating on trial data outlook By Investing.com - Investing.com South Africa
Jefferies reiterates Sarepta Therapeutics stock rating on trial data outlook By Investing.com - Investing.com Canada
Jefferies reiterates Sarepta Therapeutics stock rating on trial data outlook - Investing.com India
Jefferies reiterates Sarepta Therapeutics stock rating on trial data outlook By Investing.com - Investing.com UK
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower - Benzinga
Mizuho reiterates Sarepta stock rating after Novartis trial miss By Investing.com - Investing.com South Africa
Mizuho reiterates Sarepta stock rating after Novartis trial miss By Investing.com - Investing.com Nigeria
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Reuters
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Yahoo Finance
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year - BioSpace
Why is Sarepta Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Why is Sarepta Therapeutics stock sliding today? By Investing.com - Investing.com India
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year - Business Wire
Why is Sarepta Therapeutics stock sliding today? - Investing.com
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Novartis drops 13% on trial failure, dragging Dyne and Sarepta (NVS:NYSE) - Seeking Alpha
Sarepta Therapeutics (SRPT) Stock Analysis: Navigating the Biotech Landscape with Innovative Therapies - DirectorsTalk Interviews
Sarepta Therapeutics Faces Investor Investigations – 8-5 - stl.news
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc.SRPT - PR Newswire
Why Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report? - Yahoo Finance
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - finance.yahoo.com
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Potential Upside In Biotech Amidst Revenue Challenges - DirectorsTalk Interviews
Sarepta Therapeutics (SRPT) Could Be 30% Undervalued After Elevidys Progress Hopes - Sahm
CytomX Therapeutics, Inc. (CTMX) Stock Price & News - Syfe
Sarepta Therapeutics (SRPT) Could Be 30% Undervalued After Elevidys Progress Hopes - simplywall.st
Sarepta: A Prove-It Story Now Defined By ELEVIDYS Execution - Seeking Alpha
SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data — Retail Eyes ‘Monumental Comeback’ - Stocktwits
Sarepta (SRPT) Stock Looks Fully Valued As Sales Trail Fair Value - Yahoo Finance
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc.SRPT - Business Wire
Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 9.2%Here's Why - MarketBeat
Sarepta Therapeutics Delivers Q2 Operating Profit as CEO Transition Advances Pipeline - Streetwise Reports
Sarepta Therapeutics Jumps 8.6% Amid Sector-Wide Rally - AlphaStreet
Sarepta Therapeutics Delivers Q2 Operating Profit as CEO Transition Advances Pipeline - Streetwise Reports
Sarepta Therapeutics Inc (SRPT) 財務データ
収益
当期純利益
現金流量
EPS
Sarepta Therapeutics Inc (SRPT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| STEPHEN MAYO | Director |
Mar 12 '26 |
Proposed Sale |
17.02 |
7,239 |
123,175 |
0 |
| Estepan Ian Michael | Chief Operating Officer |
Feb 26 '26 |
Option Exercise |
13.71 |
7,450 |
102,140 |
200,750 |
| Nicaise Claude | Director |
Jan 29 '26 |
Option Exercise |
13.71 |
10,500 |
143,955 |
38,312 |
| BEHRENS M KATHLEEN | Director |
Jan 27 '26 |
Option Exercise |
13.71 |
10,500 |
143,955 |
203,976 |
| Estepan Ian Michael | Chief Operating Officer |
Dec 16 '25 |
Sale |
22.31 |
13,187 |
294,202 |
193,300 |
| IAN M ESTEPAN | Officer |
Dec 16 '25 |
Proposed Sale |
22.31 |
13,187 |
294,145 |
0 |
大文字化:
|
ボリューム (24 時間):